BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 11249494)

  • 1. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.
    Hamilton K; Clair EW
    Expert Opin Pharmacother; 2000 Jul; 1(5):1041-52. PubMed ID: 11249494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.
    Mikuls TR; Moreland LW
    Expert Opin Pharmacother; 2001 Jan; 2(1):75-84. PubMed ID: 11336570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    Feldmann M; Maini RN
    Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.
    Shanahan JC; St Clair W
    Clin Immunol; 2002 Jun; 103(3 Pt 1):231-42. PubMed ID: 12173297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives for TNF-alpha-targeting therapies.
    Lorenz HM; Kalden JR
    Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S17-24. PubMed ID: 12110119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept in rheumatoid arthritis.
    Alldred A
    Expert Opin Pharmacother; 2001 Jul; 2(7):1137-48. PubMed ID: 11583065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.
    Moreland LW
    Pharmacoeconomics; 2004; 22(2 Suppl 1):39-53. PubMed ID: 15157003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New disease modifying agents in adult rheumatoid arthritis.
    Koh ET
    Ann Acad Med Singap; 2001 Mar; 30(2):170-3. PubMed ID: 11379415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.
    Sørensen J; Andersen LS
    Pharmacoeconomics; 2005; 23(3):289-98. PubMed ID: 15836009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C; Dougados M
    BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic approaches to the management of rheumatoid arthritis.
    Hughes LB; Moreland LW
    BioDrugs; 2001; 15(6):379-93. PubMed ID: 11520249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R; Takeuchi T; Eguchi K; Miyasaka N;
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].
    Pérez Pampín E; Gómez-Reino Carnota JJ
    Med Clin (Barc); 2008 Feb; 130(5):179-87. PubMed ID: 18341834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.